Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update

Immix Biopharma, Inc. (NASDAQ:IMMXGet Free Report) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 489,900 shares, an increase of 123.2% from the January 15th total of 219,500 shares. Approximately 6.4% of the shares of the company are sold short. Based on an average daily trading volume, of 340,700 shares, the days-to-cover ratio is presently 1.4 days.

Immix Biopharma Trading Down 5.6 %

NASDAQ IMMX opened at $3.06 on Tuesday. The company has a 50 day moving average of $5.30 and a 200-day moving average of $3.92. Immix Biopharma has a 1-year low of $1.40 and a 1-year high of $7.75.

Insider Transactions at Immix Biopharma

In other news, Director Jason Hsu bought 31,000 shares of the company’s stock in a transaction dated Monday, December 11th. The stock was bought at an average price of $4.67 per share, with a total value of $144,770.00. Following the completion of the acquisition, the director now owns 813,000 shares of the company’s stock, valued at $3,796,710. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 55.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Immix Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC acquired a new stake in shares of Immix Biopharma during the 2nd quarter worth $29,000. XTX Topco Ltd acquired a new stake in Immix Biopharma during the first quarter worth about $31,000. Susquehanna International Group LLP acquired a new stake in Immix Biopharma during the first quarter worth about $32,000. Tocqueville Asset Management L.P. bought a new position in Immix Biopharma in the 3rd quarter valued at about $41,000. Finally, BlackRock Inc. acquired a new position in shares of Immix Biopharma in the 2nd quarter valued at approximately $42,000. 3.97% of the stock is owned by institutional investors and hedge funds.

Immix Biopharma Company Profile

(Get Free Report)

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.

Featured Articles

Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with's FREE daily email newsletter.